These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 30865835)
1. Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. Mathai SC; Hemnes AR; Manaker S; Anguiano RH; Dean BB; Saundankar V; Classi P; Nelsen AC; Gordon K; Ventetuolo CE Ann Am Thorac Soc; 2019 Jul; 16(7):797-806. PubMed ID: 30865835 [TBL] [Abstract][Full Text] [Related]
2. Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. Burger CD; Pruett JA; Lickert CA; Berger A; Murphy B; Drake W J Manag Care Spec Pharm; 2018 Mar; 24(3):291-302. PubMed ID: 29406840 [TBL] [Abstract][Full Text] [Related]
3. Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review. Gillmeyer KR; Lee MM; Link AP; Klings ES; Rinne ST; Wiener RS Chest; 2019 Apr; 155(4):680-688. PubMed ID: 30471268 [TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882 [TBL] [Abstract][Full Text] [Related]
6. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of code-based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases. Sprecher VP; Didden EM; Swerdel JN; Muller A Pulm Circ; 2020; 10(4):2045894020961713. PubMed ID: 33240487 [TBL] [Abstract][Full Text] [Related]
8. Development and Validation of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. Gillmeyer KR; Nunez ER; Rinne ST; Qian SX; Klings ES; Wiener RS Chest; 2021 May; 159(5):1986-1994. PubMed ID: 33345949 [TBL] [Abstract][Full Text] [Related]
9. High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. Shah NB; Mitchell RE; Proctor ST; Choi L; DeClercq J; Jolly JA; Hemnes AR; Zuckerman AD PLoS One; 2019; 14(6):e0217798. PubMed ID: 31170217 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T Curr Med Res Opin; 2011 Sep; 27(9):1763-8. PubMed ID: 21793646 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan. Natali S; Palmieri M; Polidori C Eur J Hosp Pharm; 2020 Mar; 27(2):100-102. PubMed ID: 32133136 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Tran-Duy A; Morrisroe K; Clarke P; Stevens W; Proudman S; Sahhar J; Nikpour M; J Am Heart Assoc; 2021 Apr; 10(7):e015816. PubMed ID: 33759539 [TBL] [Abstract][Full Text] [Related]
13. Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension. McConnell J; Bilir SP; Xu Y; Tsang Y; Panjabi S J Med Econ; 2023; 26(1):1349-1355. PubMed ID: 37800591 [TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. Dufour R; Pruett J; Hu N; Lickert C; Stemkowski S; Tsang Y; Lane D; Drake W J Med Econ; 2017 Nov; 20(11):1178-1186. PubMed ID: 28762848 [TBL] [Abstract][Full Text] [Related]
15. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management. Correale M; Tricarico L; Grazioli D; Formica ES; Petrucci R; Persichella P; Di Biase M; Brunetti ND Cardiovasc Drugs Ther; 2019 Dec; 33(6):725-738. PubMed ID: 31811420 [TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. Copher R; Cerulli A; Watkins A; Laura Monsalvo M J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140 [TBL] [Abstract][Full Text] [Related]
18. Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database. Heresi GA; Dean BB; Castillo H; Lee HF; Classi P; Stafkey-Mailey D; Kantorovich A; Morland K; Sketch MR; Wu BS; King CS Lung; 2022 Apr; 200(2):187-203. PubMed ID: 35348836 [TBL] [Abstract][Full Text] [Related]
19. Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension. Zhang C; Tsang Y; He J; Panjabi S Adv Ther; 2023 May; 40(5):2481-2492. PubMed ID: 37024760 [TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data. Gauthier-Loiselle M; Tsang Y; Lefebvre P; Agron P; Royer J; Bell Lynum KS; Bennett L; Panjabi S Curr Med Res Opin; 2022 Jun; 38(6):1019-1030. PubMed ID: 35243952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]